Prasinezumab is a monoclonal antibody that selectively binds aggregated alpha-synuclein. Prasinezumab is under investigation as a disease-modifying therapeutic candidate for early-stage Parkinsons disease, where it is being evaluated for its ability to interfere with pathogenic alpha-synuclein aggregation and progression of neurodegeneration.
Reinheit:
0.975
CAS Nummer:
[1960462-19-4]
Target-Kategorie:
Others
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten